IMGN : Analysis & Opinions

  1. 3 Plays for the Biotech Bear Market (GILD, UTHR)

    March 8, 2016
    These short plays should profit from the developing bear market in the biotech sector.
  2. Analyzing Arena Pharma's Return on Equity (ARNA, IMGN)

    March 8, 2016
    Explore Arena Pharmaceutical's return on equity (ROE) and find out what is driving its significant negative returns. Find ...
  3. Invest in Cancer Research with These 3 Stocks

    May 20, 2015
    These cancer research stocks offer both a high ceiling and the potential to save lives.
  4. 3 Ways Arena Can Boost Shareholder Value (ARNA, IMGN)

    April 2, 2015
    Following the approval of weight control management drug Belviq by the Food and Drug Administration in 2012, Arena Pharmaceuticals ...
  5. Eli Lilly Among Healthcare's Biggest Movers on August 27, 2012

    August 27, 2012
    The market is on the rise this morning. The Nasdaq is up 0.5%; the S&P 500 has risen 0.3%; and the Dow has climbed 0.1%. ...
  6. Another Setback For Roche Is Bad News For ImmunoGen

    August 27, 2010
    Roche suffers another setback to its key cancer franchise, while ImmunoGen faces a major delay in royalty payments.
Trading Center